Association of empagliflozin treatment with albuminuria levels in patients with heart failure: a secondary analysis of EMPEROR-Pooled : original investigation
Albuminuria, routinely assessed as spot urine albumin-to-creatinine ratio (UACR), indicates structural damage of the glomerular filtration barrier and is associated with poor kidney and cardiovascular outcomes. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to reduce UACR in patie...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
September 21, 2022
|
| In: |
JAMA cardiology
Year: 2022, Jahrgang: 7, Heft: 11, Pages: 1148-1159 |
| ISSN: | 2380-6591 |
| DOI: | 10.1001/jamacardio.2022.2924 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1001/jamacardio.2022.2924 Verlag, lizenzpflichtig, Volltext: https://jamanetwork.com/journals/jamacardiology/fullarticle/2796744 
|
| Verfasserangaben: | João Pedro Ferreira, Faiez Zannad, Javed Butler, Gerasimos Filippatos, Stuart J. Pocock, Martina Brueckmann, Dominik Steubl, Elke Schueler, Stefan D. Anker, Milton Packer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1891417622 | ||
| 003 | DE-627 | ||
| 005 | 20241205142933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240618s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1001/jamacardio.2022.2924 |2 doi | |
| 035 | |a (DE-627)1891417622 | ||
| 035 | |a (DE-599)KXP1891417622 | ||
| 035 | |a (OCoLC)1475299836 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pedro Ferreira, João |e VerfasserIn |0 (DE-588)1239313632 |0 (DE-627)1767400063 |4 aut | |
| 245 | 1 | 0 | |a Association of empagliflozin treatment with albuminuria levels in patients with heart failure |b a secondary analysis of EMPEROR-Pooled : original investigation |c João Pedro Ferreira, Faiez Zannad, Javed Butler, Gerasimos Filippatos, Stuart J. Pocock, Martina Brueckmann, Dominik Steubl, Elke Schueler, Stefan D. Anker, Milton Packer |
| 264 | 1 | |c September 21, 2022 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.06.2024 | ||
| 520 | |a Albuminuria, routinely assessed as spot urine albumin-to-creatinine ratio (UACR), indicates structural damage of the glomerular filtration barrier and is associated with poor kidney and cardiovascular outcomes. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have been found to reduce UACR in patients with type 2 diabetes, but its use in patients with heart failure (HF) is less well studied.To analyze the association of empagliflozin with study outcomes across baseline levels of albuminuria and change in albuminuria in patients with HF across a wide range of ejection fraction levels.This post hoc analysis included all patients with HF from the EMPEROR-Pooled analysis using combined individual patient data from the international multicenter randomized double-blind parallel-group, placebo-controlled EMPEROR-Reduced and EMPEROR-Preserved trials. Participants in the original trials were excluded from this analysis if they were missing baseline UACR data. EMPEROR-Preserved was conducted from March 27, 2017, to April 26, 2021, and EMPEROR-Reduced was conducted from April 6, 2017, to May 28, 2020. Data were analyzed from January to June 2022.Randomization to empagliflozin or placebo.New-onset macroalbuminuria and regression to normoalbuminuria and microalbuminuria.A total of 9673 patients were included (mean [SD] age, 69.9 [10.4] years; 3551 [36.7%] female and 6122 [63.3%] male). Of these, 5552 patients had normoalbuminuria (UACR <30 mg/g) and 1025 had macroalbuminuria (UACR >300 mg/g). Compared with normoalbuminuria, macroalbuminuria was associated with younger age, races other than White, obesity, male sex, site region other than Europe, higher levels of N-terminal pro-hormone brain natriuretic peptide and high-sensitivity troponin T, higher blood pressure, higher New York Heart Association class, greater HF duration, more frequent previous HF hospitalizations, diabetes, hypertension, lower eGFR, and less frequent use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and mineralocorticoid receptor antagonists. An increase in events was observed in individuals with higher UACR levels. The association of empagliflozin with cardiovascular mortality or HF hospitalization was consistent across UACR categories (hazard ratio [HR], 0.80; 95% CI, 0.69-0.92 for normoalbuminuria; HR, 0.74; 95% CI, 0.63-0.86 for microalbuminuria; HR, 0.78; 95% CI, 0.63-0.98 for macroalbuminuria; interaction P trend = .71). Treatment with empagliflozin was associated with lower incidence of new macroalbuminuria (HR, 0.81; 95% CI, 0.70-0.94; P = .005) and an increase in rate of remission to sustained normoalbuminuria or microalbuminuria (HR, 1.31; 95% CI, 1.07-1.59; P = .009) but not with a reduction in UACR in the overall population; however, UACR was reduced in patients with diabetes, who had higher UACR levels than patients without diabetes (geometric mean for diabetes at baseline, 0.91; 95% CI, 0.85-0.98 and for no diabetes at baseline, 1.08; 95% CI, 1.01-1.16; interaction P = .008).In this post hoc analysis of a randomized clinical trial, compared with placebo, empagliflozin was associated with reduced HF hospitalizations or cardiovascular death irrespective of albuminuria levels at baseline, reduced progression to macroalbuminuria, and reversion of macroalbuminuria.ClinicalTrials.gov Identifiers: NCT03057977 and NCT03057951 | ||
| 700 | 1 | |a Zannad, Faiez |e VerfasserIn |4 aut | |
| 700 | 1 | |a Butler, Javed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pocock, Stuart J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Steubl, Dominik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schueler, Elke |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anker, Stefan D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Packer, Milton |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAMA cardiology |d Chicago, Ill. : American Medical Association, 2016 |g 7(2022), 11, Seite 1148-1159 |h Online-Ressource |w (DE-627)86003531X |w (DE-600)2857185-X |w (DE-576)470106948 |x 2380-6591 |7 nnas |a Association of empagliflozin treatment with albuminuria levels in patients with heart failure a secondary analysis of EMPEROR-Pooled : original investigation |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:11 |g pages:1148-1159 |g extent:12 |a Association of empagliflozin treatment with albuminuria levels in patients with heart failure a secondary analysis of EMPEROR-Pooled : original investigation |
| 787 | 0 | 8 | |i Errata |a Mazzanti, A. |t Association of empagliflozin treatment with albuminuria levels in patients with heart failure: a secondary analysis of EMPEROR-Pooled (Sept, 10.1001/jamacardio.2022.2924, 2022), in: JAMA Cardiol. |d 2022 |g Vol. 7(11), 1177-1177 |o 10.1001/jamacardio.2022.4032 |
| 856 | 4 | 0 | |u https://doi.org/10.1001/jamacardio.2022.2924 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://jamanetwork.com/journals/jamacardiology/fullarticle/2796744 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240618 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 6 | ||
| 999 | |a KXP-PPN1891417622 |e 4539707310 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedDisp":"September 21, 2022","dateIssuedKey":"2022"}],"relHost":[{"part":{"volume":"7","pages":"1148-1159","year":"2022","issue":"11","extent":"12","text":"7(2022), 11, Seite 1148-1159"},"name":{"displayForm":["American Medical Association"]},"disp":"Association of empagliflozin treatment with albuminuria levels in patients with heart failure a secondary analysis of EMPEROR-Pooled : original investigationJAMA cardiology","pubHistory":["Vol 1, no. 1 (April 2016)-"],"origin":[{"publisherPlace":"Chicago, Ill.","dateIssuedDisp":"[2016]-","publisher":"American Medical Association"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"title":[{"title":"JAMA cardiology","title_sort":"JAMA cardiology"}],"note":["Gesehen am 14.11.24"],"recId":"86003531X","physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"id":{"zdb":["2857185-X"],"issn":["2380-6591"],"eki":["86003531X"]}}],"name":{"displayForm":["João Pedro Ferreira, Faiez Zannad, Javed Butler, Gerasimos Filippatos, Stuart J. Pocock, Martina Brueckmann, Dominik Steubl, Elke Schueler, Stefan D. Anker, Milton Packer"]},"physDesc":[{"extent":"12 S."}],"id":{"eki":["1891417622"],"doi":["10.1001/jamacardio.2022.2924"]},"language":["eng"],"recId":"1891417622","person":[{"role":"aut","given":"João","display":"Pedro Ferreira, João","family":"Pedro Ferreira","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Faiez","roleDisplay":"VerfasserIn","display":"Zannad, Faiez","family":"Zannad"},{"given":"Javed","role":"aut","display":"Butler, Javed","family":"Butler","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Gerasimos","display":"Filippatos, Gerasimos","family":"Filippatos","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","display":"Pocock, Stuart J.","family":"Pocock","role":"aut","given":"Stuart J."},{"given":"Martina","role":"aut","display":"Brückmann, Martina","family":"Brückmann","roleDisplay":"VerfasserIn"},{"role":"aut","given":"Dominik","family":"Steubl","display":"Steubl, Dominik","roleDisplay":"VerfasserIn"},{"given":"Elke","role":"aut","roleDisplay":"VerfasserIn","family":"Schueler","display":"Schueler, Elke"},{"role":"aut","given":"Stefan D.","roleDisplay":"VerfasserIn","family":"Anker","display":"Anker, Stefan D."},{"given":"Milton","role":"aut","roleDisplay":"VerfasserIn","display":"Packer, Milton","family":"Packer"}],"title":[{"title":"Association of empagliflozin treatment with albuminuria levels in patients with heart failure","subtitle":"a secondary analysis of EMPEROR-Pooled : original investigation","title_sort":"Association of empagliflozin treatment with albuminuria levels in patients with heart failure"}],"note":["Gesehen am 18.06.2024"],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a PEDROFERREASSOCIATIO2120 | ||